Sany Group and Fosun contributed to a $61.4m round for the third-party drug development services provider, which counts Jilin Aodong Medicine as an earlier backer.
China-based drug development services provider Thousand Oaks Biopharmaceuticals has raised over RMB400m ($61.4m) in a series C round featuring heavy equipment manufacturer Sany Group and conglomerate Fosun, DealStreetAsia reported yesterday.
GL Ventures, the venture capital arm of hedge fund manager Hillhouse Capital, co-led the round, with Chinese state-owned investment vehicle, Capital Venture Investment Fund. Sany participated through private equity arm Sany Foundation while Fosun invested through a sub-fund.
The round was also backed by CDH Investments and US-China Green Fund…
